# A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

> **NCT01231620** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 626 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** Zanamivir
- **DRUG:** Placebo to match zanamivir
- **DRUG:** Oseltamivir
- **DRUG:** Placebo to match oseltamivir

## Key facts

- **NCT ID:** NCT01231620
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-15
- **Primary completion:** 2015-03-18
- **Final completion:** 2015-03-18
- **Target enrollment:** 626 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231620, "A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01231620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*